Literature DB >> 908034

Mechanism of tumor cell resistance to lysis by syngeneic lymphocytes.

I J Fidler, C Bucana.   

Abstract

B16 melanoma variant lines, which resisted lysis by syngeneic lymphocytes, were selected in vitro by repeated exposure of the tumor cells to purified cytotoxic lymphocytes. The resistance of the tumor cells to lysis mediated by syngeneic lymphocytes was not accompanied by a loss or masking of major histocompatibility antigens. Neither the lymphocyte-susceptible B16 (F10) nor the lymphocyte-resistant B16 (F10Lr) cells grew in allogeneic recipients, and both were destroyed in vitro by allogeneic lymphocytes. The resistance to lysis by syngeneic lymphocytes was not accompanied by loss or masking of receptors for macrophage recognition and destruction. F10Lr cells did not protect F10 cells from lymphocyte-mediated lysis in cocultivation experiments. Immunization of syngeneic mice in vivo with B16-F10 cells successfully protected mice against challenge with B16-F10 cells. However, mice immunized with B16-F10Lr cells were not protected against challenge with B16-F10 cells. B16-F10Lr cells were not immunogenic when tested under this condition. Light, scanning, and transmission electron microscopic studies of tumor cell-lymphocyte interaction suggested that the resistance of B16-F10Lr cells to destruction by syngeneic lymphocytes in vitro was due to the masking or absence of tumor-specific antigen(s) present on the lymphocyte-susceptible F10 cells.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 908034

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  Mouse model for pre-clinical study of human cancer immunotherapy.

Authors:  Zhiya Ya; Yared Hailemichael; Willem Overwijk; Nicholas P Restifo
Journal:  Curr Protoc Immunol       Date:  2015-02-02

2.  B16 as a mouse model for human melanoma.

Authors:  W W Overwijk; N P Restifo
Journal:  Curr Protoc Immunol       Date:  2001-05

3.  Heterogeneous expression of a murine B16 melanoma-associated antigen correlates with cell cycle.

Authors:  S P Leong; P D Noguchi; R E Cunningham; T Takami; J A Roth
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

Review 4.  Mouse models of metastatic pancreatic adenocarcinoma.

Authors:  K Xie; B Wang; Q Shi; J L Abbruzzese; Q Xiong; X Le
Journal:  Int J Pancreatol       Date:  2001

5.  The mechanism of T-cell mediated cytotoxicity. VI. T-cell projections and their role in target cell killing.

Authors:  C J Sanderson; A M Glauert
Journal:  Immunology       Date:  1979-01       Impact factor: 7.397

6.  Immunoselection of tumor variants resistant to antibody-mediated cytotoxicity. Their immunologic and metastatic characterization.

Authors:  J R Starkey; W C Davis; J E Talmadge
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

7.  Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice.

Authors:  Kathleen M Kokolus; Ying Zhang; Jeffrey M Sivik; Carla Schmeck; Junjia Zhu; Elizabeth A Repasky; Joseph J Drabick; Todd D Schell
Journal:  Oncoimmunology       Date:  2017-12-21       Impact factor: 8.110

Review 8.  Biology of human colon cancer metastasis.

Authors:  M Gutman; I J Fidler
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

Review 9.  Immunology of metastasis. Can the immune response cope with disseminated tumor?

Authors:  P Frost; R S Kerbel
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

10.  The selective nature of metastasis.

Authors:  J E Talmadge
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.